Serum urate and probability of dopaminergic deficit in early "Parkinson's disease"

Movement Disorders

Volumn 26, Issue 10, 2011, Pages 1864-1868

  Schwarzschild, Michael A ^a   Marek, Kenneth ^b   Eberly, Shirley ^c   Oakes, David ^c   Shoulson, Ira ^c   Jennings, Danna ^b   Seibyl, John ^b   Ascherio, Alberto ^d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biomarker; Diagnosis; Dopamine transporter; Neuroimaging; Parkinson's disease; Urate

Indexed keywords

DOPAMINE TRANSPORTER; IODINE I 125 2 BETA CARBOXYMETHOXY 3 BETA(4 IODOPHENYL)TROPANE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; URATE;

ADULT; ARTICLE; BRAIN SCINTISCANNING; CENTRAL NERVOUS SYSTEM DISEASE; CROSS-SECTIONAL STUDY; DOPAMINERGIC DEFICIT; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PARKINSON DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URIC ACID BLOOD LEVEL;

ADULT; AGED; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; PROBABILITY; RETROSPECTIVE STUDIES; SEX FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; URIC ACID;

EID: 80052199119     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23741     Document Type: Article

References (26)

1. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981; 78: 6858-6862.
2. Burkhardt CR, Weber HK. Parkinson's disease: a chronic, low-grade antioxidant deficiency? Med Hypotheses 1994; 43: 111-114.
3. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58: 495-505.
4. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996; 144: 480-484.
5. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005; 58: 797-800.
6. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007; 166: 561-567.
7. Chen H, Mosley TH, Alonso A, Huang X. Plasma Urate and Parkinson's Disease in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2009; 169: 1064-1069.
8. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008; 167: 831-838.
9. Facheris MF, Hicks AA, Minelli C, et al. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J Mol Neurosci 2011; 43: 243-250.
10. Marek K, Seibyl J. Beta-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-cit study: long-term imaging assessment. Neurology 2003; 60(Suppl 1): A298.
11. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101.
12. Marek K, Jennings D, Seibyl J, The Parkinson Study Group. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study [abstract]. Neurology 2005; 64(Suppl 1): A274.
13. The Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007; 69: 1480-1490.
14. Marras C, McDermott MP, Rochon PA, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005; 64: 87-93.
15. Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001; 57: 2089-2094.
16. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004; 61: 1224-1229.
17. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med 2010; 4: 701-712.
18. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson's disease. Arch Neurol 2008; 65: 716-723.
19. Ascherio A, Lewitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66: 1460-1468.
20. Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, et al. Olfaction in patients with suspected Parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 2009; 80: 744-748.
21. Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord 2010; 25: 560-569.
22. Ponsen MM, Stoffers D, Wolters EC, Booij J, Berendse HW. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81: 396-399.
23. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
24. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 2006; 27: 933-937.
25. Antonini A. Imaging for early differential diagnosis of parkinsonism. Lancet Neurol 2010; 9: 130-131.
26. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870.